

SIXTH SUPPLEMENT DATED 21 JANUARY 2022

TO CREDIT SUISSE INTERNATIONAL REGISTRATION DOCUMENT DATED 29 JUNE 2021 AND THE PROSPECTUSES LISTED IN SCHEDULE 1

This supplement (the “**Sixth Supplement**”) dated 21 January 2022 supplements the Registration Document dated, and approved by the *Commission de Surveillance du Secteur Financier* (the “**CSSF**”) on, 29 June 2021 (the “**Registration Document**”), and the prospectuses listed in Schedule 1 hereto, and constitutes the sixth supplement to the Registration Document for the purposes of Article 10(1) and Article 23(5) of Regulation (EU) 2017/1129. The terms used but not defined in this Sixth Supplement have the same meaning as such terms used in the Registration Document.

This Sixth Supplement is supplemental to, and should be read in conjunction with, the Registration Document as supplemented by the first supplement to the Registration Document dated 22 July 2021, the second supplement to the Registration Document dated 24 August 2021, the third supplement to the Registration Document dated 29 October 2021, the fourth supplement to the Registration Document dated 16 November 2021 and the fifth supplement to the Registration Document dated 20 December 2021 (collectively, the “**Existing Supplements**”), including the documents incorporated by reference therein. To the extent that there is any inconsistency between (a) any statement in this Sixth Supplement or any statement or information incorporated by reference into the Registration Document by this Sixth Supplement, (b) any other statement or information in or incorporated by reference into the Registration Document as supplemented by the Existing Supplements, and/or (c) any other statement or information in or incorporated by reference into the prospectuses listed in Schedule 1 hereto, the statements or information in (a) above will prevail.

This Sixth Supplement has been produced to (i) incorporate by reference specified portions of the Form 6-K Dated 18 January 2022 (as defined below), (ii) update the sections of the Registration Document titled “General Information—6. Names and Addresses of Directors and Executives” (page 28), and “Appendix 1 – Information for the purposes of Art. 26(4) of the Regulation (EU) 2017/1129” (page A-1), and (iii) provide information about changes to the Board of Directors of CSG and CS.

Information Incorporated by Reference

The section of the Registration Document titled “Information Incorporated by Reference” (pages 17 to 23) is hereby amended to include the following information:

Form 6-K Dated 18 January 2022

- The Form 6-K of CSG and CS filed with the SEC on 18 January 2022 (the “**Form 6-K Dated 18 December 2022**”), which contains a media release titled “Credit Suisse Group appoints Axel P. Lehmann as new Chairman; António Horta-Osório has resigned,” as indicated in the cross-reference table below.

Form 6-K Dated 18 January 2022			Page(s) of the PDF
	Form 6-K	Entire document except for the sentence “Further information about Credit Suisse can be found at www.credit-suisse.com .”	1 to 6

The information identified in the above table is incorporated by reference into, and forms part of, the Registration Document (and any information not listed in the above table but included in the Form 6-K Dated 18 January 2022 is not incorporated by reference into the Registration Document and either (a) is covered elsewhere in the Registration Document as supplemented by the Existing Supplements and this Sixth Supplement, or (b) is not relevant for investors).

Only the portions of the Form 6-K Dated 18 January 2022 specified in the above table have been incorporated by reference into the Registration Document, and not, for the avoidance of doubt, any other parts of such document or the websites referred to in this Sixth Supplement.

A copy of the Form 6-K Dated 18 January 2022 can be obtained, free of charge, on the website of CS (<https://www.credit-suisse.com/>) at:

- <https://www.credit-suisse.com/media/assets/about-us/docs/investor-relations/financial-regulatory-disclosures/regulatory-disclosures/company-registration-documents/form-6-k-dated-18-january-2022.pdf> (the Form 6-K Dated 18 January 2022).

Amendments to the section titled “6. Names and Addresses of Directors and Executives” in the Registration Document

The section headed “General Information—6. Names and Addresses of Directors and Executives” beginning on page 28 of the Registration Document (as supplemented) is hereby amended to include the following information:

Clare Brady ceased to be a Director of CSi with effective date 31 December 2021.

As of 31 December 2021, the composition of the Board of Directors was as follows:

- John Devine (Chair and Independent Non-Executive)
- David Mathers – Chief Executive Officer (CEO)
- Debra Davies (Independent Non-Executive)
- Doris Honold (Independent Non-Executive)
- Christopher Horne (Deputy CEO)
- Caroline Waddington – Chief Financial Officer (CFO)
- Jonathan Moore
- Nicola Kane

Changes to the Board of Directors of CSG and CS

On 17 January 2022, CSG and CS announced the appointment of Axel Lehmann as the new Chairman of the Board of Directors of CSG and CS effective immediately. He succeeds António Horta-Osório, who resigned from the Board of Directors of CSG and CS effective on the same date. Following his appointment by the Board of Directors of CSG and CS, Axel Lehmann has taken office as Chairman. The Board of Directors of CSG and CS will also propose him for election as Chairman at their respective upcoming Annual General Meetings on 29 April 2022.

Effective 17 January 2022, the composition of the Board of Directors of CS* is as follows:

Name	Function
Axel Lehmann	Chairman, Chairman of the Risk Committee
Iris Bohnet	
Clare Brady	
Juan Colombas	
Christian Gellerstad	Chair Conduct and Financial Crime Control Committee
Michael Klein	
Shan Li	
Seraina Macia	
Blythe Masters	
Richard Meddings	Chair Audit Committee
Kai S. Nargolwala	Chair Compensation Committee
Ana Paula Pessoa	
Severin Schwan	Vice-Chair and Lead Independent Director

*The composition of the Board of Directors of CS is the same as the composition of the Board of Directors of CSG.

There are no conflicts of interest between the private interests or other duties of the members of the Board of Directors listed above and their respective duties to CS.

General

For the purposes of Art. 23(5) of the Regulation (EU) 2017/1129, this Sixth Supplement forms a constituent part of, and supplements and amends, the prospectuses listed in Schedule 1 hereto.

For the avoidance of doubt, the information included in Appendix 1 hereto amends and restates in its entirety the section headed "APPENDIX 1 – INFORMATION FOR THE PURPOSES OF ART. 26(4) OF THE REGULATION (EU) 2017/1129" in the Registration Document.

This Sixth Supplement and the documents incorporated by reference into the Registration Document by this Sixth Supplement have been filed with the CSSF, and copies of the Registration Document, the Existing Supplements, this Sixth Supplement and the documents incorporated by reference into the Registration Document (as supplemented by the Existing Supplements and this Sixth Supplement) will be available, free of charge, on the website of the Luxembourg Stock Exchange at www.bourse.lu and on the Issuer's website at: <https://www.credit-suisse.com/be/en/investment-banking/financial-regulatory/international.html>.

Except for the copies of the documents incorporated by reference into the Registration Document (as supplemented by the Existing Supplements and this Sixth Supplement) that are available on the Luxembourg Stock Exchange website (<https://www.bourse.lu/home>) or the Issuer's website, no information contained on the websites to which links have been provided is incorporated by reference in the Registration Document.

Save as disclosed in the Existing Supplements and this Sixth Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Registration Document has arisen or been noted, as the case may be, since the publication of the Registration Document.

In accordance with Article 23(2a) of Regulation (EU) 2017/1129, investors who have already agreed to purchase or subscribe for securities pursuant to the prospectuses listed in Schedule 1 hereto before this Sixth Supplement is published have the right, exercisable within three working days after the publication of this Sixth Supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy referred to in Article 23(1) of Regulation (EU) 2017/1129 arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first. In connection therewith, investors should contact the Distributor (as defined in the relevant prospectus) of such securities. The final date of the right of withdrawal will be 26 January 2022.

Responsibility Statement

The Issuer takes responsibility for the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement. Having taken all reasonable care to ensure that such is the case, the information contained in the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement, is, to the best knowledge of the Issuer, in accordance with the facts and contains no omission likely to affect its import.

This Sixth Supplement is not for use in, and may not be delivered to or inside, the United States.

SCHEDULE 1 – LIST OF PROSPECTUSES TO WHICH THIS SUPPLEMENT RELATES

1. Securities Note comprising part of the Trigger Redeemable and Phoenix Securities Base Prospectus dated 9 July 2021.
2. Securities Note comprising part of the Put and Call Securities Base Prospectus dated 14 July 2021.
3. Securities Note comprising part of the Reverse Convertible and Worst of Reverse Convertible Securities Base Prospectus dated 15 July 2021.
4. Securities Note comprising part of the Bonus and Participation Securities Base Prospectus dated 16 July 2021.

APPENDIX 1 – INFORMATION FOR THE PURPOSES OF ART. 26(4) OF THE REGULATION (EU) 2017/1129

[Binding English language version:]

KEY INFORMATION ON THE ISSUER				
Who is the Issuer of the Securities?				
Domicile and legal form, law under which the Issuer operates and country of incorporation				
CSi is incorporated under English law as an unlimited liability company domiciled in England and Wales and which operates under English law. Its Legal Entity Identifier (LEI) is E58DKGMJYYYYJLN8C3868.				
Issuer's principal activities				
The principal activities of CSi are banking, including the trading of derivative products linked to interest rates, foreign exchange, equities, commodities and credit.				
Major shareholders, including whether it is directly or indirectly owned or controlled and by whom				
CSi is an indirect wholly owned subsidiary of Credit Suisse Group AG.				
Key managing directors				
<p style="margin-left: 20px;">Board of Directors</p> <ul style="list-style-type: none"> <li style="width: 50%;">• John Devine, Non-Executive Chair <li style="width: 50%;">• Caroline Waddington <li style="width: 50%;">• Christopher Horne <li style="width: 50%;">• Jonathan Moore <li style="width: 50%;">• David Mathers <li style="width: 50%;">• Nicola Kane <li style="width: 50%;">• Doris Honold <li style="width: 50%;">• Debra Jane Davies 				
Statutory auditors				
PricewaterhouseCoopers LLP, 1 Embankment Place, London, WC2N 6RH.				
What is the key financial information regarding the Issuer?				
CSi derived the key financial information included in the tables below as of and for the years ended 31 December 2020 and 2019 from the 2020 CSi Annual Report. The key information included in the table below as of and for the six months ended 30 June 2021 and 30 June 2020 was derived from the 2021 CSi H1 Interim Report.				
<i>CSi consolidated statement of income</i>				
(USD million)	Year ended 31 December 2020 (audited)	Year ended 31 December 2019 (audited) ¹	Interim 6 months ended 30 June 2021 (unaudited)	Interim 6 months ended 30 June 2020 (unaudited) ²
Net interest income	10	228	(39)	18
Commission and fee income	363	340	183	207

¹ 2019 numbers have been restated to disclose the effect of adjustments related to offsetting of centrally cleared derivative transactions. Further details relating to restatement are included in Note 2- Significant Accounting Policies.

² 6M20 numbers have been restated to disclose the impact of discontinued operations and adjustment relating to negative interest on cash collateral. Details relating to discontinued operations are included in Note 19 – Discontinued Operations and Assets and Liabilities Held for Sale.

Allowance for credit losses	(17)	(4)	(4,736)	(22)
Net gains/(losses) from financial assets/liabilities at fair value through profit or loss	1,715	1,321	695	1,065
Net revenues	2,312	2,049	(3,744)	1,385
Net profit attributable to Credit Suisse International shareholders	211	336	(5,094)	404

CSi consolidated statement of financial position

(USD million)	As of 30 June 2021 (unaudited)	Year ended 31 December 2020 (audited)	Year ended 31 December 2019 (audited)
Total assets	258,377	290,246	226,248
Borrowings	6,923	2,436	14,116
Debt in issuance – Senior	32,248	31,179	13,600
Debt in issuance – Subordinated	420	418	408
Net loans ³	3,036	3,151	3,103
Deposits ⁴	565	433	435
Total shareholders' equity	17,850	23,007	22,786

What are the key risks that are specific to the Issuer?

The Issuer is subject to the following key risks:

- Liquidity risk arising from potential inability to borrow or access the capital markets on suitably favourable terms or to sell its assets. This may also arise from increased liquidity costs.
- The Issuer may suffer significant losses from its credit exposures, which exist across a wide range of transactions and counterparties and may be exacerbated by adverse market conditions (including the impact of COVID-19), increased volatility in certain markets or instruments or disruption in the liquidity or transparency of financial markets. In addition, disruptions in the liquidity or transparency of the financial markets may result in the Issuer's inability to sell, syndicate or realise the value of its positions, thereby leading to increased concentrations. Any inability to reduce these positions may not only increase the market and credit risks associated with such positions, but also increase the level of risk-weighted assets on the Issuer's balance sheet, thereby increasing its capital requirements, all of which could adversely affect its businesses. Default or concerns of default by one or more large financial institutions could negatively impact the Issuer's business and the financial market generally, and the Issuer's credit risk exposure will increase if the collateral it holds cannot be realised at prices sufficient to cover the full amount of the exposure. The suspension and ongoing liquidation of certain supply chain finance funds and the failure of a US-based hedge fund to meet its margin commitments (and CSi's exit from its positions relating thereto) may continue to have negative consequences for CSi.
- Market fluctuations, volatility relating to the Issuer's trading and investment activities (against which its hedging strategies may not prove effective), uncertainties regarding the possible discontinuation of benchmark rates and adverse economic conditions may impact the Issuer's financial condition and results of operations. The spread of COVID-19 and resulting tight government controls and containment measures implemented around the world have caused severe disruption to global supply chains and economic activity, and the market has entered a period of significantly increased volatility. The spread of COVID-19 is currently having an adverse impact on the global economy, the severity and duration of which is difficult to predict. This has adversely affected, and may continue to adversely affect, the

³ Net Loans are renamed as 'Loans and Advances' to better describe the nature of items under the heading.

⁴ Deposits are renamed as 'Due to banks' to better describe the nature of items under the heading.

Issuer's business, operations and financial performance. This impact is likely to continue and to affect the Issuer's credit loss estimates, mark-to-market losses, trading revenues and net interest income, as well as the Issuer's ability to successfully realise its strategic objectives. To the extent the COVID-19 pandemic continues to adversely affect the global economy, and/or adversely affects the Issuer's business, operations or financial performance, it may also have the effect of increasing the likelihood and/or magnitude of other risks described herein, or may pose other risks which are not presently known to the Issuer or not currently expected to be significant to its business, operations or financial performance. The Issuer is closely monitoring the potential adverse effects and impact on its operations, businesses and financial performance, including liquidity and capital usage, though the extent of the impact is difficult to fully predict at this time due to the continuing evolution of this uncertain situation. The Issuer's financial position and cash flows are exposed to foreign currency exchange fluctuations, and this and other market risks could exacerbate other risks to which the Issuer is exposed.

4. The Issuer is exposed to risks from adverse market conditions and unfavourable economic, monetary, political, legal, regulatory and other developments in the countries in which it operates, including ongoing uncertainty over the outcome of the negotiations surrounding the withdrawal of the UK from the European Union, following which the Issuer may not be able to transact legally with the European Union. An element of the strategy of Credit Suisse Group AG and its consolidated subsidiaries is to increase its private banking businesses in emerging market countries. The Issuer's implementation of this strategy will increase its exposure to economic instability in those countries, which could result in significant losses.
5. The Issuer's existing risk management procedures and policies may not always be effective, particularly in highly volatile markets, and may not fully mitigate its risk exposure in all markets or against all types of risk. Moreover, the Issuer's actual results may differ materially from its estimates and valuations, which are based on judgment and available information and rely on predictive models and processes. The same is true of the Issuer's accounting treatment of off-balance sheet entities, including special purpose entities, which requires it to exercise significant management judgment in applying accounting standards; these standards (and their interpretation) have changed and may continue to change. In addition, the Issuer's business may be disrupted by technology-related failures such as service outages or information security incidents, and the Issuer could be compromised by cyber incidents.
6. The Issuer's exposure to legal risks is significant and difficult to predict and the volume and amount of damages claimed in litigation, regulatory proceedings and other adversarial proceedings against financial services firms continues to increase in many of the principal markets in which the Issuer operates. If the Issuer fails to manage these risks effectively, this could lead to a decrease in the value of its securities. Regulations applicable to the Issuer (as well as regulations and changes in enforcement practices applicable to its clients) may adversely affect its business and ability to execute its strategic plans. In addition, the applicable resolution and bail-in legislation (including the Banking Act 2009) may affect the Issuer's security holders, who would have very limited rights to challenge the exercise of the bail-in tool, any resolution power or any pre-resolution measure.
7. The Issuer is exposed to the risk that improper behaviour or judgement, misconduct, or non-compliance with policies or regulations by the Issuer's employees results in negative financial, non-financial or reputational impacts on its clients, employees, the Issuer and the financial markets. In addition, the Issuer's position in the highly competitive financial services industry could be harmed by damage to its reputation arising from the factors mentioned above or failures of the Issuer's procedures and controls.